negative control sgrna (mod Search Results


90
Synthego Inc negative control scrambled sgrna
Negative Control Scrambled Sgrna, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/negative control scrambled sgrna/product/Synthego Inc
Average 90 stars, based on 1 article reviews
negative control scrambled sgrna - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Genechem negative control sgrnas
ACSL4 mediates DGLA-induced ferroptosis. ( a ) Western blot showing ACSL4 protein levels in Kasumi-1 cells expressing negative control sgRNA <t>(sgNC)</t> or ACSL4-targeting sgRNA (sgACSL4). ( b ) Cell viability of Kasumi-1 cells expressing sgNC or sgACSL4 treated with erastin for 24 h. ( c ) Cell viability of Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA for 24 h. ( d - f )The levels of lipid ROS ( d ), MDA ( e ), and Fe 2+ ( f ) in Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 µM) for 24 h. ( g ) TEM images of Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 μM) for 24 h. Scale bars: upper panel, 1 μm; lower panel, 500 nm. White arrows indicate normal mitochondria, red arrows indicate abnormal mitochondrial structure, yellow arrows indicate lipid droplets. Data are shown as mean ± SD, n = 3 biologically independent experiments, ** p < 0.01, *** p <0.001.
Negative Control Sgrnas, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/negative control sgrnas/product/Genechem
Average 90 stars, based on 1 article reviews
negative control sgrnas - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Merck & Co sgrna targeting human nlrc5 (sgrna-1 5’-gctgcagaagtgtcagctccagg
A, Schematic representation of hematopoietic reconstitution of lethally irradiated recipient mice with fetal liver derived donor HSPCs. Fetal liver cells from double transgenic Eμ-MYC/Cas9 E13.5 donor embryos (an abundant source of HSPCs) were lentivirally transduced with vectors <t>encoding</t> <t>BFP</t> or CFP as a marker and sgRNAs targeting Tfap4 (sgTfap4 ), a positive <t>sgRNA</t> targeting Trp53 (sgTrp53 ) or a negative non-targeting control sgRNA ( sgControl ). These transduced donor fetal liver cells were then transplanted into lethally irradiated C57BL/6-Ly5.1 recipient mice. Tumour-free survival of recipient mice was measured as days post-transplantation. Hematopoietic tissues and peripheral blood were harvested from tumour burdened recipient mice for further analysis. B, Kaplan-Meier survival curve showing tumour-free survival of mice transplanted with either of two vectors containing a sgTfap4 , a positive control sgTrp53 or a negative sgControl . N indicates number of sick mice/number of mice transplanted with sgRNA transduced HSPCs for each sgRNA. Median survival post transplantation in days is indicated in brackets. **** P < 0.0001.
Sgrna Targeting Human Nlrc5 (Sgrna 1 5’ Gctgcagaagtgtcagctccagg, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sgrna targeting human nlrc5 (sgrna-1 5’-gctgcagaagtgtcagctccagg/product/Merck & Co
Average 90 stars, based on 1 article reviews
sgrna targeting human nlrc5 (sgrna-1 5’-gctgcagaagtgtcagctccagg - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


ACSL4 mediates DGLA-induced ferroptosis. ( a ) Western blot showing ACSL4 protein levels in Kasumi-1 cells expressing negative control sgRNA (sgNC) or ACSL4-targeting sgRNA (sgACSL4). ( b ) Cell viability of Kasumi-1 cells expressing sgNC or sgACSL4 treated with erastin for 24 h. ( c ) Cell viability of Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA for 24 h. ( d - f )The levels of lipid ROS ( d ), MDA ( e ), and Fe 2+ ( f ) in Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 µM) for 24 h. ( g ) TEM images of Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 μM) for 24 h. Scale bars: upper panel, 1 μm; lower panel, 500 nm. White arrows indicate normal mitochondria, red arrows indicate abnormal mitochondrial structure, yellow arrows indicate lipid droplets. Data are shown as mean ± SD, n = 3 biologically independent experiments, ** p < 0.01, *** p <0.001.

Journal: Translational Oncology

Article Title: Exogenous dihomo-γ-linolenic acid triggers ferroptosis via ACSL4-mediated lipid metabolic reprogramming in acute myeloid leukemia cells

doi: 10.1016/j.tranon.2024.102227

Figure Lengend Snippet: ACSL4 mediates DGLA-induced ferroptosis. ( a ) Western blot showing ACSL4 protein levels in Kasumi-1 cells expressing negative control sgRNA (sgNC) or ACSL4-targeting sgRNA (sgACSL4). ( b ) Cell viability of Kasumi-1 cells expressing sgNC or sgACSL4 treated with erastin for 24 h. ( c ) Cell viability of Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA for 24 h. ( d - f )The levels of lipid ROS ( d ), MDA ( e ), and Fe 2+ ( f ) in Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 µM) for 24 h. ( g ) TEM images of Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 μM) for 24 h. Scale bars: upper panel, 1 μm; lower panel, 500 nm. White arrows indicate normal mitochondria, red arrows indicate abnormal mitochondrial structure, yellow arrows indicate lipid droplets. Data are shown as mean ± SD, n = 3 biologically independent experiments, ** p < 0.01, *** p <0.001.

Article Snippet: The corresponding sgRNAs were designed and cloned into the vector, and negative control sgRNAs (sgNC) were generated as controls (Genechem, China).

Techniques: Western Blot, Expressing, Negative Control

ACSL4 reprograms DGLA-associated lipids. ( a ) Lipids were analyzed by LC-MS/MS. Heatmap shows lipids fold-changes in Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 µM). ( b ) Distribution of fatty acid chains of species from lipids in ( a ) that were down-regulated upon DGLA treatment. ( c ) Pie chart, by PUFA chain subclass, showing proportions of each lipid species in the down-regulated lipids upon DGLA treatment. ( d ) Pie charts, by phospholipid subclass, showing proportions of lipid species containing DGLA that were identified in ( a ). Data are shown as mean ± SD, n = 3 biologically independent experiments.

Journal: Translational Oncology

Article Title: Exogenous dihomo-γ-linolenic acid triggers ferroptosis via ACSL4-mediated lipid metabolic reprogramming in acute myeloid leukemia cells

doi: 10.1016/j.tranon.2024.102227

Figure Lengend Snippet: ACSL4 reprograms DGLA-associated lipids. ( a ) Lipids were analyzed by LC-MS/MS. Heatmap shows lipids fold-changes in Kasumi-1 cells expressing sgNC or sgACSL4 treated with DGLA (20 µM). ( b ) Distribution of fatty acid chains of species from lipids in ( a ) that were down-regulated upon DGLA treatment. ( c ) Pie chart, by PUFA chain subclass, showing proportions of each lipid species in the down-regulated lipids upon DGLA treatment. ( d ) Pie charts, by phospholipid subclass, showing proportions of lipid species containing DGLA that were identified in ( a ). Data are shown as mean ± SD, n = 3 biologically independent experiments.

Article Snippet: The corresponding sgRNAs were designed and cloned into the vector, and negative control sgRNAs (sgNC) were generated as controls (Genechem, China).

Techniques: Liquid Chromatography with Mass Spectroscopy, Expressing

Deletion of ACSL4 inhibits the anticancer activity of DGLA in vivo . ( a ) Hypodermic injection of Kasumi-1 cells stably transfected with sgNC or sgACSL4 into BALB/c nude mice and treated with DGLA or vehicle, established subcutaneous xenograft tumors (n = 6 mice/group). ( b ) Tumor images show the relative sizes of the xenograft tumors formed by Kasumi-1 cells expressing sgNC or sgACSL4 and treated with DGLA or vehicle on day 18. ( c ) Changes in tumor volumes over time for mice implanted with Kasumi-1 cells expressing sgNC or sgACSL4 and treated with DGLA or vehicle. ( d - e ) Measures of tumor volume ( d )and tumor weight ( e ) values of mice at the study endpoint. ( f - h ) The levels of lipid ROS ( f ), MDA ( g ), and Fe 2+ ( h ) in xenograft tumors treated with vehicle or DGLA for 18 days (n = 6 tumor samples from different animals per group). ( i ) TEM images of mitochondria ultrastructure in xenograft tumors treated with DGLA or vehicle for 18 days. Scale bars: upper panel, 1 μm; lower panel, 500 nm. White arrows indicate normal mitochondria, red arrows indicate abnormal mitochondrial structure, yellow arrows indicate lipid droplets. Data are shown as mean ± SD, ** p < 0.01, *** p <0.001.

Journal: Translational Oncology

Article Title: Exogenous dihomo-γ-linolenic acid triggers ferroptosis via ACSL4-mediated lipid metabolic reprogramming in acute myeloid leukemia cells

doi: 10.1016/j.tranon.2024.102227

Figure Lengend Snippet: Deletion of ACSL4 inhibits the anticancer activity of DGLA in vivo . ( a ) Hypodermic injection of Kasumi-1 cells stably transfected with sgNC or sgACSL4 into BALB/c nude mice and treated with DGLA or vehicle, established subcutaneous xenograft tumors (n = 6 mice/group). ( b ) Tumor images show the relative sizes of the xenograft tumors formed by Kasumi-1 cells expressing sgNC or sgACSL4 and treated with DGLA or vehicle on day 18. ( c ) Changes in tumor volumes over time for mice implanted with Kasumi-1 cells expressing sgNC or sgACSL4 and treated with DGLA or vehicle. ( d - e ) Measures of tumor volume ( d )and tumor weight ( e ) values of mice at the study endpoint. ( f - h ) The levels of lipid ROS ( f ), MDA ( g ), and Fe 2+ ( h ) in xenograft tumors treated with vehicle or DGLA for 18 days (n = 6 tumor samples from different animals per group). ( i ) TEM images of mitochondria ultrastructure in xenograft tumors treated with DGLA or vehicle for 18 days. Scale bars: upper panel, 1 μm; lower panel, 500 nm. White arrows indicate normal mitochondria, red arrows indicate abnormal mitochondrial structure, yellow arrows indicate lipid droplets. Data are shown as mean ± SD, ** p < 0.01, *** p <0.001.

Article Snippet: The corresponding sgRNAs were designed and cloned into the vector, and negative control sgRNAs (sgNC) were generated as controls (Genechem, China).

Techniques: Activity Assay, In Vivo, Injection, Stable Transfection, Transfection, Expressing

A, Schematic representation of hematopoietic reconstitution of lethally irradiated recipient mice with fetal liver derived donor HSPCs. Fetal liver cells from double transgenic Eμ-MYC/Cas9 E13.5 donor embryos (an abundant source of HSPCs) were lentivirally transduced with vectors encoding BFP or CFP as a marker and sgRNAs targeting Tfap4 (sgTfap4 ), a positive sgRNA targeting Trp53 (sgTrp53 ) or a negative non-targeting control sgRNA ( sgControl ). These transduced donor fetal liver cells were then transplanted into lethally irradiated C57BL/6-Ly5.1 recipient mice. Tumour-free survival of recipient mice was measured as days post-transplantation. Hematopoietic tissues and peripheral blood were harvested from tumour burdened recipient mice for further analysis. B, Kaplan-Meier survival curve showing tumour-free survival of mice transplanted with either of two vectors containing a sgTfap4 , a positive control sgTrp53 or a negative sgControl . N indicates number of sick mice/number of mice transplanted with sgRNA transduced HSPCs for each sgRNA. Median survival post transplantation in days is indicated in brackets. **** P < 0.0001.

Journal: bioRxiv

Article Title: Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis

doi: 10.1101/2022.12.19.520971

Figure Lengend Snippet: A, Schematic representation of hematopoietic reconstitution of lethally irradiated recipient mice with fetal liver derived donor HSPCs. Fetal liver cells from double transgenic Eμ-MYC/Cas9 E13.5 donor embryos (an abundant source of HSPCs) were lentivirally transduced with vectors encoding BFP or CFP as a marker and sgRNAs targeting Tfap4 (sgTfap4 ), a positive sgRNA targeting Trp53 (sgTrp53 ) or a negative non-targeting control sgRNA ( sgControl ). These transduced donor fetal liver cells were then transplanted into lethally irradiated C57BL/6-Ly5.1 recipient mice. Tumour-free survival of recipient mice was measured as days post-transplantation. Hematopoietic tissues and peripheral blood were harvested from tumour burdened recipient mice for further analysis. B, Kaplan-Meier survival curve showing tumour-free survival of mice transplanted with either of two vectors containing a sgTfap4 , a positive control sgTrp53 or a negative sgControl . N indicates number of sick mice/number of mice transplanted with sgRNA transduced HSPCs for each sgRNA. Median survival post transplantation in days is indicated in brackets. **** P < 0.0001.

Article Snippet: A vector constitutively expressing a negative control sgRNA targeting human NLRC5 (sgRNA-1 5’-GCTGCAGAAGTGTCAGCTCCAGG) and the BFP tag was also obtained from the Merck CRISPR glycerol stock arrayed whole mouse genome sgRNA library, and this vector was used for the pre-leukemic analyzes.

Techniques: Irradiation, Derivative Assay, Transgenic Assay, Transduction, Marker, Transplantation Assay, Positive Control